{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:00:13Z","timestamp":1785405613333,"version":"3.56.0"},"reference-count":72,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Directorate of Research and Development, Universitas Indonesia","award":["PKS-55\/UN2.RST\/HKP.05.00\/2025"],"award-info":[{"award-number":["PKS-55\/UN2.RST\/HKP.05.00\/2025"]}]},{"award":["PKS-55\/UN2.RST\/HKP.05.00\/2025"],"award-info":[{"award-number":["PKS-55\/UN2.RST\/HKP.05.00\/2025"]}],"id":[{"id":"https:\/\/ror.org\/0116zj450","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Indonesian Endowment Fund for Education","award":["4302\/B3\/DT.03.08\/2025"],"award-info":[{"award-number":["4302\/B3\/DT.03.08\/2025"]}]},{"name":"Indonesian Endowment Fund for Education","award":["573\/PKS\/R\/UI\/2025"],"award-info":[{"award-number":["573\/PKS\/R\/UI\/2025"]}]},{"award":["4302\/B3\/DT.03.08\/2025"],"award-info":[{"award-number":["4302\/B3\/DT.03.08\/2025"]}],"id":[{"id":"https:\/\/ror.org\/05p2xef58","id-type":"ROR","asserted-by":"publisher"}]},{"award":["573\/PKS\/R\/UI\/2025"],"award-info":[{"award-number":["573\/PKS\/R\/UI\/2025"]}],"id":[{"id":"https:\/\/ror.org\/05p2xef58","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>The discovery of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and its role in promoting the degradation of the low-density lipoprotein receptor (LDLR) has revolutionized lipid-lowering therapy, offering new therapy for patients with hypercholesterolemia. Notably, PCSK9 is now being explored for functions beyond lipid regulation. Emerging evidence implicates PCSK9 in vascular pathology by influencing endothelial dysfunction, inflammatory signaling, oxidative stress, and vascular homeostasis\u2014potentially through LDLR-independent mechanisms. This review critically evaluates PCSK9\u2019s potential as a regulator of endothelial dysfunction, synthesizing findings from in vitro, in vivo, and clinical studies. While current PCSK9-targeted therapies, including monoclonal antibodies and siRNA-based agents, have demonstrated robust efficacy in lowering lipid levels and reducing cardiovascular risk, their direct effects on endothelial PCSK9 signaling remain unclear. On the other hand, novel approaches\u2014such as peptide-based inhibitors, intracellular modulation, and natural compounds\u2014resulted in new insights into endothelial-specific PCSK9 pathways. Overall, this review highlights the need to bridge experimental and clinical evidence by applying endothelial-focused models, multi-omics analyses, and functional vascular assessments to clarify the role of PCSK9 in endothelial dysfunction and to propose future strategies for cardiovascular interventions targeting PCSK9-mediated endothelial dysfunction.<\/jats:p>","DOI":"10.3390\/ijms27146473","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:35:52Z","timestamp":1784630152000},"page":"6473","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PCSK9 as a Potential Regulator of Endothelial Dysfunction: Mechanistic Insights and Future Directions"],"prefix":"10.3390","volume":"27","author":[{"given":"Anisa Qisti","family":"Mathriul","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia, UI Depok Campus, Depok 16424, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maharani Hestu Mukti","family":"Wisesa","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia, UI Depok Campus, Depok 16424, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-706X","authenticated-orcid":false,"given":"Vicko","family":"Suswidiantoro","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia, UI Depok Campus, Depok 16424, West Java, Indonesia"},{"name":"Laboratory of Pharmacology and Toxicology, Pharmacy Department, Faculty of Health, Universitas Aisyah Pringsewu, Pringsewu 35372, Lampung, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-8627","authenticated-orcid":false,"given":"Meidi Utami","family":"Puteri","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok 16424, West Java, Indonesia"},{"name":"National Metabolomics Collaborative Research Center, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok 16424, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9905-2473","authenticated-orcid":false,"given":"Mitsuyasu","family":"Kato","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia, UI Depok Campus, Depok 16424, West Java, Indonesia"},{"name":"Department of Experimental Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-8915","authenticated-orcid":false,"given":"Fadlina Chany","family":"Saputri","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok 16424, West Java, Indonesia"},{"name":"National Metabolomics Collaborative Research Center, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok 16424, West Java, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wang, Z., Yang, Y., Wang, Q., Wang, L., Zhao, Y., Qian, X., Feng, R., and Qian, J. (2026). Pathological mechanisms and clinical research progress of endothelial dysfunction. Front. Cardiovasc. Med., 13.","DOI":"10.3389\/fcvm.2026.1749548"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1002\/mco2.651","article-title":"Endothelial dysfunction: Molecular mechanisms and clinical implications","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Botts, S.R., Fish, J.E., and Howe, K.L. (2021). Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.787541"},{"key":"ref_5","unstructured":"Kumar, V., Abbas, A.K., and Aster, J.C. (2018). Robbins Basic Pathology, Elsevier. [10th ed.]."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"44885","DOI":"10.31083\/RCM44885","article-title":"Endothelial Cell-Derived PCSK9 in Atherosclerosis: Pathophysiological Roles and Therapeutic Perspectives","volume":"26","author":"Wang","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: A key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ. Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Xia, X.D., Peng, Z.S., Gu, H.M., Wang, M., Wang, G.Q., and Zhang, D.W. (2021). Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.764038"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ying, Q., Chan, D.C., and Watts, G.F. (2021). New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.603910"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: Regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","article-title":"Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels","volume":"220","author":"Ferri","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e70011","DOI":"10.1002\/jbt.70011","article-title":"MiR-148a-3p mitigation of coronary artery disease through PCSK9\/NF-\u03baB inhibition of vascular endothelial cell injury","volume":"38","author":"Tang","year":"2024","journal-title":"J. Biochem Mol. Toxicol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1194\/jlr.M078360","article-title":"PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction","volume":"59","author":"Sun","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.numecd.2022.06.020","article-title":"Relationship between PCSK9 and endothelial function in patients with acute myocardial infarction","volume":"32","author":"Cimaglia","year":"2022","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11010-011-1028-6","article-title":"PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl\/Bax-caspase9-caspase3 pathway","volume":"359","author":"Wu","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3892\/mmr.2017.6803","article-title":"Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.21037\/atm-22-4652","article-title":"PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis","volume":"10","author":"Kong","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s11658-023-00482-5","article-title":"MiR-15b-5p and PCSK9 inhibition reduces lipopolysaccharide-induced endothelial dysfunction by targeting SIRT4","volume":"28","author":"Martino","year":"2023","journal-title":"Cell Mol. Biol. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3892\/ijmm.2021.4886","article-title":"PCSK9 mediates the oxidative low-density lipoprotein-induced pyroptosis of vascular endothelial cells via the UQCRC1\/ROS pathway","volume":"47","author":"Zeng","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3390\/encyclopedia2040111","article-title":"Apoptosis Regulators Bcl-2 and Caspase-3","volume":"2","author":"Hussar","year":"2022","journal-title":"Encyclopedia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1006\/jmcc.2001.1419","article-title":"Endothelial cell apoptosis: Biochemical characteristics and potential implications for atherosclerosis","volume":"33","author":"Choy","year":"2001","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Niu, Y., Wang, L., Zhang, Y., Zou, Y., and Zhou, C. (2025). Pyroptosis in cardiovascular diseases: Roles, mechanisms, and clinical implications. Front. Cardiovasc. Med., 12, Erratum in Front. Cardiovasc. Med. 2025, 12, 1680298.","DOI":"10.3389\/fcvm.2025.1629016"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pipitone, R.M., Calvaruso, V., Di Marco, L., Di Salvo, F., Gaggianesi, M., Lupo, G., Zito, R., La Mantia, C., Ramazzotti, M., and Petta, S. (2022). Mer Tyrosine Kinase (MERTK) modulates liver fibrosis progression and hepatocellular carcinoma development. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.926236"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.7150\/thno.83914","article-title":"PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging","volume":"13","author":"Liu","year":"2023","journal-title":"Theranostics"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Li, Y., Wittchen, E.S., Monaghan-Benson, E., Hahn, C., Earp, H.S., Doerschuk, C.M., and Burridge, K. (2019). The role of endothelial MERTK during the inflammatory response in lungs. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0225051"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s43088-025-00694-y","article-title":"PCSK9 molecular bridge between hyperlipidemia and vascular inflammation: Novel insights into PCSK9-centered pathways in atherosclerosis: A comprehensive review","volume":"14","author":"Desouky","year":"2025","journal-title":"Beni Suef Univ. J. Basic Appl. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zulkapli, R., Muid, S.A., Wang, S.M., and Nawawi, H. (2023). PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065098"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cvr\/cvz313","article-title":"PCSK9 and inflammation: Role of shear stress, pro-inflammatory cytokines, and LOX-1","volume":"116","author":"Ding","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Ding","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5830491","DOI":"10.1155\/2024\/5830491","article-title":"Atherosclerosis and Toll-Like Receptor4 (TLR4), Lectin-Like Oxidized Low-Density Lipoprotein-1 (LOX-1), and Proprotein Convertase Subtilisin\/Kexin Type9 (PCSK9)","volume":"2024","author":"Bagheri","year":"2024","journal-title":"Mediat. Inflamm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12979-023-00383-3","article-title":"Toll-like receptor 4 (TLR4): New insight immune and aging","volume":"20","author":"Kim","year":"2023","journal-title":"Immun. Ageing"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-7258(02)00236-X","article-title":"LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: Implications in endothelial dysfunction and atherosclerosis","volume":"95","author":"Chen","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1089\/ars.2014.6054","article-title":"Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta","volume":"22","author":"Ding","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10753-022-01715-z","article-title":"PCSK9 Promotes Endothelial Dysfunction During Sepsis Via the TLR4\/MyD88\/NF-\u03baB and NLRP3 Pathways","volume":"46","author":"Huang","year":"2023","journal-title":"Inflammation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"531","DOI":"10.7150\/thno.80289","article-title":"SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells","volume":"13","author":"Prattichizzo","year":"2023","journal-title":"Theranostics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.7150\/thno.45922","article-title":"Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acs.jmedchem.3c01634","article-title":"Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds","volume":"67","author":"Ouyang","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41598-018-35819-0","article-title":"Biological Characterization of Computationally Designed Analogs of peptide TVFTSWEEYLDWV (Pep2-8) with Increased PCSK9 Antagonistic Activity","volume":"9","author":"Lammi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Adorni, M.P., Zimetti, F., Lupo, M.G., Ruscica, M., and Ferri, N. (2020). Naturally occurring PCSK9 inhibitors. Nutrients, 12.","DOI":"10.3390\/nu12051440"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Abduljabbar, M.H. (2024). PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression. Pharmaceuticals, 17.","DOI":"10.3390\/ph17121581"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1038\/s41598-019-47242-0","article-title":"Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice","volume":"9","author":"Schuster","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/ehjcvp\/pvad051","article-title":"Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: The impact of PCSK9 inhibition","volume":"9","author":"Ziogos","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N -acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Chen, H., Hong, L., Wang, H., Li, B., Zhang, M., Li, J., Yang, L., and Liu, F. (2023). Inclisiran: A new generation of lipid-lowering siRNA therapeutic. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1260921"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/15548627.2019.1688556","article-title":"ATTEC: A potential new approach to target proteinopathies","volume":"16","author":"Li","year":"2020","journal-title":"Autophagy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8190","DOI":"10.1021\/acs.jmedchem.4c02915","article-title":"PCSK9 Targeted Autophagosome-Tethering Compounds: Design, Synthesis, and Antiatherosclerosis Evaluation","volume":"68","author":"Wu","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nsmb.3453","article-title":"Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists","volume":"24","author":"Zhang","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1074\/jbc.M113.514067","article-title":"Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_53","first-page":"5932315","article-title":"Brazilin from Caesalpinia sappan L. as a Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibitor: Pharmacophore-Based Virtual Screening, In Silico Molecular Docking, and In Vitro Studies","volume":"2023","author":"Iqbal","year":"2023","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Han, D., Ma, T., Sun, S., Zhang, Y., and Song, L. (2023). Brazilin inhibits the inflammatory immune response induced by LPS in THP-1 cells. Res. Sq.","DOI":"10.21203\/rs.3.rs-2727104\/v1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.athplu.2024.12.004","article-title":"Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9","volume":"59","author":"Palumbo","year":"2025","journal-title":"Atheroscler. Plus"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Liu, J., Zeng, X., Lin, Y.-Q., Peng, Y.-S., Liu, L., Chen, S.-H., and Du, Y.-H. (2025). The Marine Compound Isaridin E Ameliorates Lipopolysaccharide-Induced Vascular Endothelial Inflammation via the Downregulation of the TLR4\/NF-\u03baB Signaling Pathway. Mar. Drugs, 23.","DOI":"10.3390\/md23040145"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"108968","DOI":"10.1016\/j.isci.2024.108968","article-title":"Brazilin is a natural product inhibitor of the NLRP3 inflammasome","volume":"27","author":"McMahon","year":"2024","journal-title":"iScience"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e38213","DOI":"10.1016\/j.heliyon.2024.e38213","article-title":"Iron chelating, antioxidant, and anti-inflammatory properties of brazilin from Caesalpinia sappan Linn","volume":"10","author":"Taveepanich","year":"2024","journal-title":"Heliyon"},{"key":"ref_59","first-page":"7284767","article-title":"Ginkgolide B Mediated Alleviation of Inflammatory Cascades and Altered Lipid Metabolism in HUVECs via Targeting PCSK-9 Expression and Functionality","volume":"2019","author":"Wang","year":"2019","journal-title":"BioMed Res. Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1002\/ptr.6177","article-title":"Ginkgolide B ameliorates oxidized low-density lipoprotein-induced endothelial dysfunction via modulating Lectin-like ox-LDL-receptor-1 and NADPH oxidase 4 expression and inflammatory cascades","volume":"32","author":"Feng","year":"2018","journal-title":"Phytother. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11944","DOI":"10.1021\/acs.jafc.2c02681","article-title":"Chemical Characterization and Atherosclerosis Alleviation Effects of Gypenosides from Gynostemma pentaphyllum through Ameliorating Endothelial Dysfunction via the PCSK9\/LOX-1 Pathway","volume":"70","author":"Huang","year":"2022","journal-title":"J. Agric. Food Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"153688","DOI":"10.1016\/j.phymed.2021.153688","article-title":"Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression","volume":"91","author":"Wang","year":"2021","journal-title":"Phytomedicine"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Li, X., Chen, Y., Wang, R., Cao, B., Deng, T., Han, J., and Yang, M. (2025). Gypenosides, a promising phytochemical triterpenoid: Research progress on its pharmacological activity and mechanism. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1705946"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zou, Y., Chen, Z., Zhang, X., Yu, J., Xu, H., Cui, J., Li, Y., Niu, Y., Zhou, C., and Xia, J. (2022). Targeting PCSK9 Ameliorates Graft Vascular Disease in Mice by Inhibiting NLRP3 Inflammasome Activation in Vascular Smooth Muscle Cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.894789"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00392-024-02556-6","article-title":"PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease","volume":"115","author":"Kannenkeril","year":"2024","journal-title":"Clin. Res. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"104513","DOI":"10.1016\/j.mvr.2023.104513","article-title":"Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function","volume":"148","author":"Schremmer","year":"2023","journal-title":"Microvasc. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacl.2018.02.004","article-title":"Improved endothelial function after short-term therapy with evolocumab","volume":"12","author":"Maulucci","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ahn, Y., Aung, N., and Ahn, H.S. (2024). A Comprehensive Review of Clinical Studies Applying Flow-Mediated Dilation. Diagnostics, 14.","DOI":"10.3390\/diagnostics14222499"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in Atherosclerosis: From Pathophysiology to Practice","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1161\/01.CIR.0000095273.92468.D9","article-title":"Endothelial Dysfunction and Cardiovascular Risk Prediction in Peripheral Arterial Disease: Additive Value of Flow-Mediated Dilation to Ankle-Brachial Pressure Index","volume":"108","author":"Brevetti","year":"2003","journal-title":"Circulation"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6473\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:14:28Z","timestamp":1784798068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":72,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27146473"],"URL":"https:\/\/doi.org\/10.3390\/ijms27146473","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}